shutterstock-179623283-web

360b / Shutterstock.com

12 August 2014Americas

Sanofi and MannKind strike Afrezza deal

French pharmaceutical company Sanofi and the US-based MannKind Corporation have entered into an exclusive licensing agreement to develop and commercialise MannKind’s Afrezza (insulin human), an inhalable insulin therapy for adults with types 1 and 2 diabetes.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims